Humacyte, Inc. is a Durham, North Carolina-based commercial-stage biotechnology company developing universally implantable, bioengineered human tissues at commercial scale. Its lead product, Symvess (the acellular tissue engineered vessel, or ATEV), received FDA approval in December 2024 for use as a vascular conduit in extremity vascular trauma repair. Beyond its approved indication, the company is advancing the ATEV in late-stage trials for arteriovenous access in hemodialysis and peripheral artery disease, and it has initiated a first-in-human Phase 2a study of its coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting.
The company holds Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for several programs, and its platform underpins a pipeline that also includes preclinical work in type 1 diabetes and pediatric heart surgery. Investors follow HUMA for its first-in-class regenerative medicine platform, its early commercial ramp, and the regulatory milestones tied to the ATEV's expansion into the dialysis-access market. When assessing comparable names in the sector, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, HUMA has advanced approximately 26%, moving from a closing price of about $0.43 in mid-October to roughly $0.54 by mid-November. The move was concentrated around the company's third-quarter earnings release on November 10, when the stock rose roughly 24% intraday on heavy volume. Shares subsequently pulled back from a post-earnings peak near $0.59 as some investors locked in gains.
The longer quarterly picture tells a more volatile story. Over the roughly three-month period, the stock has been essentially flat to modestly lower in the low single digits. That headline masks a sharp drawdown: HUMA fell from around $0.56 to $0.58 in mid-August to an intraday low near $0.34 in mid-October, before the strong November recovery. The result is a pronounced V-shaped pattern in which the recent 30-day advance has yet to fully reclaim the stock's mid-summer levels.
The primary catalyst was the third-quarter 2026 earnings report released on November 10. Humacyte reported Symvess sales of $1.0 million, a 151% sequential increase from $0.4 million in the second quarter and a 43% increase year over year. Total revenue of about $1.03 million exceeded consensus estimates by roughly 34%, while the company's net loss of $0.06 per share beat the roughly $0.10 loss analysts had expected. Hospital adoption expanded 44% sequentially, from 34 to 49 ordering sites, and management guided for fourth-quarter sales to at least double the third-quarter total.
Investors also responded to forward-looking milestones. Management confirmed that the sBLA for the ATEV in dialysis access remains on track for a November 2026 filing, supported by three Phase 3 studies, including the V007 trial published in The Lancet Digital Health and V012 data presented at ASN Kidney Week. The company additionally announced the initiation of its first-in-human Phase 2a CTEV study in coronary artery bypass grafting. On the analyst side, Piper Sandler maintained a Hold rating with a $1.00 price target, Barclays maintained a Hold, and H.C. Wainwright reiterated a Buy.
The quarter was defined by the company's commercial relaunch and a sharp repricing of its shares. Under Jim Mercadante, who joined as Chief Commercial Officer in May 2026, Humacyte rebuilt its commercial team, refined introductory pricing and education programs, and accelerated hospital onboarding. Sequential revenue growth and the expansion to 49 ordering hospitals reflected the early payoff of that strategy. Cost discipline also improved, with research and development spending declining sequentially and operating cash burn falling 37% year over year to $15.0 million in the third quarter, while cash and equivalents stood at $64.9 million.
At the same time, the stock's October sell-off reflected concerns common to pre-profitability biotech companies, including negative gross margins tied to unused production capacity, a still-modest revenue base, and the potential for future dilution. The November earnings beat and explicit fourth-quarter guidance helped reset sentiment, but the shares remain below their levels from earlier in the summer. I also checked this using Tickeron’s AI Pattern Search Engine to see how the stock compares to others in the industry.
Near-term attention centers on the planned sBLA submission for the ATEV in dialysis access and the FDA's subsequent acceptance and review-timeline decision. Investors will also watch the fourth-quarter Symvess sales trajectory against management's guidance to at least double Q3 revenue, as well as the pace of new hospital adoption and any disclosure on average selling prices and gross-margin improvement. The cash position and any future financing activity remain important given the company's ongoing operating losses. Clinical updates, including enrollment in the Phase 2a CTEV study and data presentations such as those scheduled for the VEITHsymposium, could also influence sentiment. As with any development-stage biotech, regulatory outcomes, reimbursement decisions, and broader market conditions will remain key variables.
I've found Tickeron's AI Trading Bots helpful for reviewing automated approaches across a wide range of tickers. The platform offers hundreds of AI robots that trade thousands of securities, with only the top-performing and most relevant systems highlighted for comparison. Users can evaluate different strategies, holding timeframes, and performance metrics to complement their own analysis. Those interested can explore the available bots and their recent results directly on the platform.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The Moving Average Convergence Divergence (MACD) for HUMA turned positive on October 21, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HUMA as a result. In 71 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
HUMA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for HUMA crossed bullishly above the 50-day moving average on November 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +0.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 194 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 148 of 170 cases where HUMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The 10-day RSI Indicator for HUMA moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 21 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where HUMA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HUMA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. HUMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.983) is normal, around the industry mean (3.592). P/E Ratio (-0.862) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology